Xenex Has Highest & Most Positive Mindshare from Hospitals for UV Disinfection According to KLAS Research’s New Infection Control Report
SAN ANTONIO--(BUSINESS WIRE)--Apr 3, 2019--KLAS Research, a healthcare IT data and insights company, recently interviewed healthcare facilities about their infection control initiatives, with a focus on innovative technologies (UV disinfection equipment, electronic hand-hygiene monitoring, and infection control software). KLAS researchers reported that XenexLightStrike ™ Germ-Zapping Robots™ earned the highest marks from hospitals for ultraviolet (UV) disinfection technology.
KLAS spoke with infection prevention professionals at 57 provider organizations to learn what approaches (and what vendors) are generating interest, which show the potential to deliver results, and what innovative tools organizations are looking to adopt. According to the report, Infection Control 2019: An Early Look at Innovative Technologies, among the UV disinfection vendors, “Xenex generates the most (and the most positive) mindshare—in part because they share research-validated outcomes —and they are the only vendor with interviewed customers who want to expand their machine fleet.” Xenex was identified as having the most positive feedback due to innovation, outcomes, and ease of use.
The report states: “Xenex is one of the most well-known UV-disinfection vendors. Provider organizations who consider the vendor’s equipment do so because of Xenex’s innovative technology, ease of use, and research-validated positive outcomes. Also, Xenex is the only vendor to have current customers mention wanting to expand their machine fleet.”
Irene Hahn, vice president of sales and account management for Xenex, said, “We are honored to be recognized by KLAS and the hospitals surveyed for our innovation and outcomes. There is a lot of noise in the no-touch UV disinfection space. Xenex has always believed the voice of the customer is the best indicator of our success and areas where we can improve. We are completely focused on helping healthcare facilities reach their infection rate reduction goals by working with and enhancing their existing infection prevention bundle and best practices.”
As superbugs such as Clostridium difficile (C.diff), Methicillin-resistant Staphylococcus aureus (MRSA), and Vancomycin-resistant enterococci (VRE) become more difficult to kill, hospitals are increasingly turning to Xenex’s pulsed xenon UV disinfection technology to help them keep their hospitals free of dangerous microorganisms. The robots emit intense pulses of xenon UV light to quickly disinfect rooms by destroying the microscopic pathogens that may have been missed during the manual cleaning process. Numerous healthcare facilities throughout the U.S. have credited the LightStrike robots in peer-reviewed, published studies for helping them reduce their C.diff, MRSA and Surgical Site Infection rates 46% - 100%.
About KLAS Research
KLAS is a research and insights firm on a global mission to improve healthcare delivery. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software, services and medical equipment to deliver timely, actionable reports and consulting services. KLAS represents the provider and payer voice and acts as a catalyst for improving vendor performance, highlighting healthcare industry challenges and opportunities, and helping build understanding and consensus for best practices. To learn more about KLAS, go to https://klasresearch.com/home.
Xenex’s patented Full Spectrum TM pulsed xenon UV room disinfection system is used for the advanced disinfection of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. Xenex’s mission is to save lives and reduce suffering by destroying the deadly microorganisms that cause hospital acquired infections (HAIs). The company is backed by well-known investors that include EW Healthcare Partners, Piper Jaffray Merchant Services, Malin Corporation, Battery Ventures, Tectonic Ventures, Targeted Technology Fund II and RK Ventures. For more information, visit Xenex.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190403005669/en/
CONTACT: Melinda Hart
210 240 4669
KEYWORD: UNITED STATES NORTH AMERICA TEXAS
INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY HEALTH BIOTECHNOLOGY HOSPITALS INFECTIOUS DISEASES MEDICAL DEVICES
Copyright Business Wire 2019.
PUB: 04/03/2019 11:44 AM/DISC: 04/03/2019 11:44 AM